Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Sandoz spinout last step in Novartis’ transformation into pure-play innovative medicines company

Move comes amid reorganization prioritizing multibillion growth drivers, the U.S. market

By Stephen Hansen, Associate Editor
August 25, 2022 5:07 PM UTC

In the midst of a reorganization that is prioritizing multibillion growth drivers and the U.S. market, Novartis has decided to spin out its Sandoz generics business, marking the Swiss pharma’s final step in transforming into an innovative medicines company.

After nearly a year of exploring strategic options for the Sandoz unit, Novartis AG (NYSE:NVS; SIX:NOVN) said Thursday it would commence a 100% spinout of the generics and biosimilars unit, with an expectation the separation would be completed in 2H23...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Novartis AG